The EFPIA Pipeline Review has found that in 2020 alone, around 5,000 clinical trials were initiated to investigate and develop new therapies and vaccines. Almost 50% of treatments in development are new substances, with 40% of the pipeline targeting rare diseases. Ground-breaking therapies are making more and more treatment for rare and paediatric disease possible.
How can we ensure continued innovation for children and people living with a rare disease? How can the EU Industrial and Pharmaceutical Strategy strengthen Europe’s innovation ecosystem? Building on fresh evidence brought by two reports developed by Dolon and OHE, this virtual event seeks to discuss how to address any scientific, regulatory and economic barriers to innovation and facilitate the development and access to medicines for children and people living with rare disease.
Join the conversation to outline ways forward towards lowering the remaining unmet needs.
Register here to join